Diatech developing radiolabelled interleukin-8 (IL-8):
This article was originally published in Clinica
Development of a diagnostic and therapeutic cytokine by Diatech (US) has received a $93,000 grant from the US NIH. The Londonderry, New Hampshire-based company plans to evaluate radiolabelled peptides derived from interleukin-8 as imaging agents, as well as therapeutics.
You may also be interested in...
A surge in Chinese applications for clinical trials for coronavirus treatments, and a fall in patient numbers, are complicating recruitment efforts for the most promising drugs, prompting official moves to tighten study rules.